Aptose Reports Results for the Third Quarter 2022
01 nov. 2022 16h01 HE
|
Aptose Biosciences, Inc.
─ Tuspetinib (HM43239) Dose Escalation and Exploration Phase 1/2 Trial in r/r AML Complete; Continued Superior Safety Profile and Clinical Responses Including Complete Remissions as Single Agent...
Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability
12 sept. 2022 07h30 HE
|
Aptose Biosciences, Inc.
– Initial modeling predicts up to 18-fold improvement in plasma steady-state exposure – – Supports exploration of continuous dosing of G3 formulation – – Lead clinical compound HM43239...
CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
02 juin 2022 20h10 HE
|
Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 ...
Aptose Presents Highlights from Corporate Update and KOL Event
02 juin 2022 17h30 HE
|
Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE...
Aptose Reports Results for the Fourth Quarter and Full Year 2021
22 mars 2022 16h01 HE
|
Aptose Biosciences, Inc.
- HM43239 clinical remission at 120mg expands list of potential treatable AML populations - - On track to initiate genotype-enriched expansion program for HM43239 in 2H22 - - Cash runway...
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
13 déc. 2021 16h30 HE
|
Aptose Biosciences, Inc.
HM43239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting Aptose Presents Highlights from Luxeptinib and APTO-253 and Provides Corporate Update SAN DIEGO,...
Aptose to Hold Corporate Update Monday, December 13th
29 nov. 2021 07h30 HE
|
Aptose Biosciences, Inc.
HM43239 clinical update in AML after oral presentation at 2021 ASH Annual MeetingLuxeptinib clinical update in AML and B-cell cancers SAN DIEGO and TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Aptose...
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
04 nov. 2021 09h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Reports Results for the Fourth Quarter and Full Year 2020
23 mars 2021 16h01 HE
|
Aptose Biosciences, Inc.
- Conference call and webcast at 5pm EDT today - - Company announces resignation of CFO Gregory Chow - - Luxeptinib (CG-806) continues dose escalation and evidence of clinical activity - SAN DIEGO...
Aptose Presents Highlights from ASH and Corporate Update Event
06 déc. 2020 17h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December...